LIPELLA PHARMACEUTICALS INC.
LIPO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LIPO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LIPO
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company developing LP-10 for hemorrhagic cystitis and LP-310 for oral lichen planus, with a lead candidate in late-stage development and a limited cash position of $1.9M as of September 30, 2025.
Key risk: Cash runway and going concern
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2025.
Tracking 4 pipeline candidates · 1 clinical trial for LIPELLA PHARMACEUTICALS INC..
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company developing LP-10 for hemorrhagic cystitis and LP-310 for oral lichen planus, with a lead candidate in late-stage development and a limited cash position of $1.9M as of September 30, 2025.
- Lead product candidate LP-10 is in late-stage development for hemorrhagic cystitis, with a Phase 2b protocol incorporating FDA feedback being prepared [sec · filed 2025-09-18].
- Second candidate LP-310 is being developed for oral lichen planus, alongside other preclinical programs [sec_mda · as of 2025-11-14].
- Cash and equivalents were $1.9M as of September 30, 2025, with no revenue and a net loss of $1.3M for the quarter [sec].
- The company has identified material weaknesses in internal controls and faces risks related to relisting its common stock on a national securities exchange [sec_mda · as of 2025-11-14].
- Management has expressed substantial doubt about the company's ability to continue as a going concern [sec_mda · as of 2025-11-14].
What works
- LP-10 has advanced to late-stage development with a Phase 2b protocol incorporating FDA feedback, indicating regulatory alignment [sec · filed 2025-09-18].
- The company is actively exploring strategic partnerships and collaborations to support further development [sec · filed 2025-09-18].
- Net cash provided by financing activities was $3.46M for the nine months ended September 30, 2025, from a private placement of preferred stock and warrants [sec_mda · as of 2025-11-14].
What to weigh
- Cash and equivalents were only $1.9M as of September 30, 2025, with no revenue and a net loss of $1.3M for the quarter [sec].
- The company has incurred losses since inception and its unaudited financial statements are prepared on a going concern basis, reflecting substantial doubt about its ability to continue [sec_mda · as of 2025-11-14].
- Material weaknesses in internal controls have been identified, and the company faces risks in relisting its common stock on a national securities exchange [sec_mda · as of 2025-11-14].
- Future funding requirements are uncertain and depend on numerous factors, including clinical trial outcomes and regulatory approvals [sec_mda · as of 2025-11-14].
From the filings
Quoted directly from source documents.
LP-10 is in late-stage development with a Phase 2b protocol incorporating FDA feedback.
“10 into late-stage development, including preparation of a Phase 2b protocol incorporating FDA feedback, scaling manufacturing to support larger clinical trials, and exploring strategic partnerships and collaborations.”
SEC filings · September 18, 2025
The company has a going concern qualification.
“Our unaudited condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the discharge of liabilities in the normal course of business. We have generated losses from operations since inception.”
SEC MD&A · November 14, 2025
The company has identified material weaknesses in internal controls and risks related to stock exchange listing.
“to remediate the material weaknesses we have identified in our internal controls; | | | ● | our ability to relist our common stock, par value $0.0001 per share (the "Common Stock"), on a national securities exchange;”
SEC MD&A · November 14, 2025
Risks & what to watch (4)›
Key risks
- Cash runway and going concern — With only $1.9M cash as of Sep 30, 2025 and ongoing losses, the company may not have sufficient funds to continue operations without additional financing [sec].
- Clinical and regulatory risk — LP-10 and LP-310 may fail in clinical trials or fail to obtain FDA approval, which would materially harm the business [sec_mda · as of 2025-11-14].
- Internal control weaknesses — Material weaknesses in internal controls have been identified, which could affect financial reporting and investor confidence [sec_mda · as of 2025-11-14].
- Stock exchange delisting risk — The company faces challenges in relisting its common stock on a national securities exchange, limiting liquidity and access to capital [sec_mda · as of 2025-11-14].
What to watch
- Initiation and results of the Phase 2b trial for LP-10 in hemorrhagic cystitis [sec · filed 2025-09-18].
- Ability to secure additional financing or partnerships to extend cash runway beyond $1.9M [sec].
- Progress in remediating material weaknesses in internal controls and relisting common stock [sec_mda · as of 2025-11-14].
- Any regulatory updates or clinical data for LP-310 in oral lichen planus [sec_mda · as of 2025-11-14].
Sources: SEC filings · SEC MD&A · Generated August 21, 2026 · How we verify sources →
Run LIPELLA PHARMACEUTICALS INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available LIPELLA PHARMACEUTICALS INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
6.2 months
D/E 0.58 · 0% dilution
Lead: Phase 2
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Short Interest
as of Apr 30, 2026- % of float
- 2.4%
- Days to cover
- 3.3
- Shares short
- 100,093
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LIPO short interestFrequently asked questions
What is the AI investment thesis for LIPELLA PHARMACEUTICALS INC.?
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company developing LP-10 for hemorrhagic cystitis and LP-310 for oral lichen planus, with a lead candidate in late-stage development and a limited cash position of $1.9M as of September 30, 2025.
What is LIPELLA PHARMACEUTICALS INC.'s lead drug candidate?
LIPELLA PHARMACEUTICALS INC.'s most advanced tracked candidate is lp-10 (Phase 2) for Oral Lichen Planus.
Who is the CEO of LIPELLA PHARMACEUTICALS INC.?
Dr. Jonathan Kaufman M.B.A., Ph.D. is the chief executive officer of LIPELLA PHARMACEUTICALS INC. (LIPO).
Where is LIPELLA PHARMACEUTICALS INC. headquartered?
LIPELLA PHARMACEUTICALS INC. (LIPO) is headquartered in Pittsburgh, PA, United States.
What therapeutic areas does LIPELLA PHARMACEUTICALS INC. focus on?
LIPELLA PHARMACEUTICALS INC. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.